).
• Conclusions: The case-fatality rate of patients with pneumococcal bacteremia decreased significantly between the first and second half of the study period, despite the increased prevalence of penicillin-nonsusceptible isolates. Independent risk factors for fatal outcome were coronary artery disease, neutropenia, and age 65 years or older, whereas prior respiratory tract infection and the occurrence of pneumococcal bacteremia in the second half of the study period were independent predictors of survival. HIV infection was a predisposing factor for pneumococcal bacteremia but was not a risk factor for fatal outcome.
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S treptococcus pneumoniae is a major cause of morbidity and mortality worldwide. [1] [2] [3] [4] Despite the availability of effective antimicrobials and vaccines, the mortality rate of patients with pneumococcal bacteremia is as high as it was in the 1950s (17%-34%). [5] [6] [7] [8] [9] [10] The lack of improvement in survival could be the result of increasing age and comorbidities of the patient population or may reflect a larger population of immunocompromised patients, such as human immunodeficiency virus (HIV)-infected patients or those who have undergone transplantation. [11] [12] [13] [14] [15] In addition, the incidence of drug-resistant strains of S pneumoniae increased during the 1990s in most geographic areas, rendering pneumococcal infections potentially more difficult to treat. 10, [16] [17] [18] We performed an active hospital-based surveillance of pneumococcal bacteremia in adult hospitalized patients to evaluate changes in epidemiological and microbiological characteristics during a 15-year period. We especially analyzed the changing pattern of risk factors and outcome between the first and the second half of the observation time.
For editorial comment, see page 599.
PATIENTS AND METHODS Hospital Setting
The study was conducted at the University Hospital Basel in Basel, Switzerland, a 950-bed primary and tertiary health care center. The hospital provides medical care for about 300,000 inhabitants who averaged 240,000 patientdays per year during the 15-year study period. During this period, hospital admissions averaged 23,300 per year. About 8000 blood cultures were performed annually from approximately 3400 patients. 19 The number of processed blood cultures did not significantly change over the study period. Between 9% and 12% of blood cultures were positive, and S pneumoniae was isolated in 5% to 6% of them.
Case Definition
All episodes of pneumococcal bacteremia, determined by blood culture positive for S pneumoniae from January 1, 1986, through December 31, 2000, were identified by microbiological medical records in hospitalized patients aged 18 years or older. Isolates from an individual patient were considered a single episode unless the interval between collection of the isolates was more than 30 days. Patients with episodes of polymicrobial bacteremia, positive blood cultures from hospitals elsewhere, and positive blood cultures obtained postmortem were excluded from the analysis. Bacteremia was considered hospital-acquired if the first blood culture was performed more than 72 hours after admission and the patient had no clinical syndrome compatible with pneumococcal infection at admission.
Data Collection
Patient medical records were reviewed with a standardized data-collection questionnaire to retrieve demographic, clinical, radiographic, and laboratory data, and the following data were abstracted: age, sex, ward, date of bacteremia diagnosis, length of hospital stay, need for admission to intensive care unit, clinical presentation, vital signs, chest x-ray findings, antimicrobial susceptibility test results, whether S pneumoniae was concurrently isolated from other sites, and antimicrobial treatment and outcome. Death was attributed to pneumococcal bacteremia if the patient's clinical course suggested persistent infection without evidence of another cause of death. The following risk factors for pneumococcal infection were recorded: chronic lung disease (chronic obstructive pulmonary disease and emphysema), chronic liver disease (Child-Pugh classification B and C), chronic renal failure (creatinine level, >2.5 mg/dL), congestive heart failure (New York Heart Association classes III and IV), coronary artery disease, valvular heart disease, current or previous smoking (>10 pack-years), alcoholism (as indicated in the medical record), injection drug use, diabetes mellitus (types 1 and 2), asplenia, active malignancy, upper respiratory tract infection within 7 days before bacteremia onset, organ transplantation, preexisting neutropenia (<1.0 × 10 9 /L neutrophils), HIV infection, and long-term use of corticosteroids (>25 mg prednisone equivalent/d for at least the previous month) or other immunosuppressive medications. Pneumococcal vaccination was defined as written documentation of vaccine administration between 2 weeks and 5 years before onset of symptoms.
Microbiological Data
Between 1986 and 1990, blood cultures were processed using a conventional nonautomatic technique (System DUO, BioMérieux, Durham, NC). Since 1991, blood cultures have been processed with use of an automated colorimetric detection system (BacT/ALERT, BioMérieux). 20 Antimicrobial susceptibility testing of S pneumoniae was performed with use of the broth dilution method. 21 All isolates were tested against penicillin, ceftriaxone, trimethoprim-sulfamethoxazole, clindamycin, and erythromycin or clarithromycin. For penicillin, minimal inhibitory concentrations against S pneumoniae of 0.06 µg/mL or less were regarded as susceptible, 0.12 to 1.0 µg/mL were considered intermediate, and 2.0 µg/mL or more were considered resistant. Serotyping of S pneumoniae is not performed routinely at our laboratory.
Statistical Analyses
To evaluate differences between groups, the unpaired Student t test for normally distributed continuous variables and the Mantel-Haenszel χ 2 test or 2-tailed Fisher exact test for categorical variables was used. Parameters found by univariate analyses to be of borderline statistical significance (P<.10) or those that showed biological plausibility were further analyzed by a stepwise logistic regression model (statistical package SPSS 10.0 for Windows, SPSS, Chicago, Ill). P<.05 was considered significant (2-tailed).
RESULTS

Incidence Rate
During the study period, 416 (5.2%) of the 8011 episodes of bacteremia were caused by S pneumoniae: 11 (2.6%) of 416 episodes were excluded because of inadequate data (8 episodes) and polymicrobial nature (3 episodes), and 405 episodes of pneumococcal bacteremia in 394 patients were analyzed further. The mean annual incidence of 1.78 episodes per 1000 hospital admissions (range, 0.89-2.74 episodes) or 16.0 episodes per 100,000 patient-days (range, 8.3-24.9 episodes) was stable over the study period (P=.27). The incidence of pneumococcal bacteremia was season related and inversely related to the mean atmospheric temperature of the area obtained from the Swiss National Hydrometeorological Institute ( Figure  1 ). From December through March of the entire study period, 215 episodes (53%) occurred, with a peak in December (59 episodes). Ten patients (3%) experienced 1 or more subsequent episodes of bacteremia: 9 patients had 2 episodes, and 1 patient had 3 episodes. The median time between recurrent episodes was 340 days (range, 72-1205 days). Of 11 recurrent episodes, 6 (55%) recurred within 1 year, 1 in the second year, 2 in the third year, and 2 in the fourth year. All patients with recurrent pneumococcal bacteremia had at least 1 coexisting medical condition, and none of them had a documented pneumococcal vaccination.
Patient Characteristics
Characteristics of the 405 episodes of pneumococcal bacteremia are summarized in Table 1 . Most patients were treated in a medical ward; approximately one fourth of patients needed to be admitted to an intensive care unit. In surgical wards, about one half of the episodes were hospital acquired, whereas most episodes in medical wards were community acquired (P<.001). Pneumonia was by far the most frequent site of infection (85%); in 6%, no site of infection was detected. In 52 episodes (13%), patients presented with more than 1 site of infection: 45 patients had 2, 6 patients had 3, and 1 patient had 4 sites of infection per pneumococcal episode.
In patients with pneumonia, no infiltrate was detected initially on chest radiography in 6% of the episodes; infiltrate was detected in 1 lobe in 71%, in 2 lobes in 19%, and in 3 or more lobes in 4%. Pleural effusion was present on 1 side in 23% of episodes (42 episodes on the left side and 38 on the right side) and bilaterally in 7%. S pneumoniae was isolated from respiratory secretions in 31% of episodes and from pleural exudate in 4%.
In patients with meningitis, computed tomography of the brain was performed in 20 episodes (61%); 50% of scans showed radiological abnormalities suggestive of bacterial meningitis. S pneumoniae was isolated from cerebrospinal fluid in 30 episodes (91%); in the remaining 3 patients with culture-negative meningitis, diagnoses were based on clinical signs and pathologic cerebrospinal fluid values consistent with bacterial meningitis.
In patients with sinusitis, S pneumoniae was isolated from sinus aspirate in 4 of 7 patients in whom a puncture or endoscopy was performed. In all 26 patients with sinusitis, radiological signs of sinusitis were present at admission.
Underlying Medical Conditions
In 60 episodes (15%), 1 risk factor was identified; in 95 episodes (23%), 2 risk factors were identified; in 110 episodes (27%), 3 risk factors were identified; and in 116 episodes (29%), 4 or more risk factors were identified (Table 2 ). In 6% of episodes, no underlying medical condition was found. In 46 (12%) of 394 patients, HIV infection was present. In asplenic patients, pneumococcal bacteremia occurred 1 to 29 years (median, 10 years) after splenectomy. Preexisting neutropenia was present in 11 patients (3%) with a mean neutrophil count of 0.261 × 10 9 /L (range, 0.030-0.710 × 10 9 /L). In 348 episodes (86%), patients had a medical condition for which pneumococcal vaccine is recommended. 22 However, pneumococcal vaccination was documented in the medical records of only 6 (2%) of these patients.
Clinical Outcome
The overall case-fatality rate in our study was 25% (102 of 405 episodes). In the univariate analysis, 7 conditions were associated with fatal outcome from pneumococcal bacteremia: chronic lung disease, malignancy, coronary artery disease, valvular heart disease, neutropenia, age 65 years or older, and hospital-acquired infection (Table 2 ). In contrast, prior respiratory tract infection, HIV infection, injection drug use, and the absence of any underlying medical condition were associated with better disease outcome. The case-fatality rate decreased substantially, from 33% (68 of 207 episodes) in the first half of the study to 17% (34 of 198 episodes) in the second half (P<.001) (Figure 2 ). The risk of death in the second half of the study was 0.5 (95% confidence interval [CI], 0.4-0.8) times the risk in the first half. The following differences were significant predictors for case fatality in the multivariate logistic regression analysis: coronary artery disease (P<.001; relative risk [RR], 4.3; 95% CI, 3.4-5.1), neutropenia (P=.001; RR, 3.2; 95% CI, 1.9-4.8), and age 65 years or older (P=.001; RR, 2.9; 95% CI, 1.8-4.2). Prior respiratory tract infection (P=.03; RR, 0.3; 95% CI, 0.1-0.5) and the occurrence of pneumococcal bacteremia in the second half of the study period (P=.01; RR, 0.4; 95% CI, 0.2-0.6) were independent predictors of survival.
The median length of hospital stay was 5 days (range, 1-125 days) for fatal cases compared with 14 days for nonfatal cases (range, 1-137 days). Of the 102 patients who died, 10 (10%) died within 24 hours after hospital admission; another 24 patients (24%) died on the second day, and 9 (9%) died on the third day. Among 43 patients who died within 3 days after admission, 20 patients (47%) had an underlying malignancy, 19 (44%) had a chronic lung disease, 14 (33%) had a history of alcoholism, and 2 (5%) were infected with HIV. 
Antimicrobial Use
In 384 (95%) of 405 episodes, an antimicrobial drug was administered within 48 hours after admission. As initial treatment, amoxicillin-clavulanic acid was administered in 164 episodes (40%), first-or third-generation cephalosporin in 114 episodes (28%), high-dose penicillin in 53 episodes (13%), amoxicillin in 29 episodes (7%), and other agents in 24 episodes (6%). In 83 episodes (20%), the initial antimicrobial drug was given in combination with a 
Antimicrobial Susceptibility
During the study period, we identified 14 penicillinnonsusceptible pneumococcal isolates: 12 had intermediate susceptibility to penicillin, and 2 were penicillin resistant (one in 1999 and another in 2000). Although the first isolate in our institution with intermediate susceptibility to penicillin was recognized in 1990 (in an HIV-infected injection drug user), the prevalence of penicillin-nonsusceptible pneumococci did not begin to increase until 1996 and reached 17% in 1999 (Figure 3) . Seven isolates were nonsusceptible to ceftriaxone. All ceftriaxone-nonsusceptible isolates also had intermediate susceptibility or resistance to penicillin. Resistance to macrolides increased from 0% in 1994 to 14% in 1999; during this same period, resistance to trimethoprim-sulfamethoxazole increased from 7% to 67%. Except for resistance to macrolides (28%), resistance to other antimicrobial drugs did not increase further in 
Characteristics in HIV-Infected Patients
Age distribution for episodes and for case-fatality rates among HIV-infected patients and HIV-negative or untested patients is shown in Figure 4 . The mean ± SD age of presumably HIV-negative patients was significantly higher at 63.1±18.1 years (range, 18-97 years) compared with that of HIV-infected patients at 33.2±6.6 years (range, 20-51 years) (P<.001). Of HIV-infected patients, 58% were men. The case-fatality rate in HIV-infected patients was significantly lower than in patients not infected with HIV or in those with unknown HIV status (9% vs 27%; P=.006) ( Table 2 ). CD4 lymphocyte counts (within 6 months preceding onset of pneumococcal bacteremia) were available for 27 (59%) of the 46 HIV-infected patients. The median CD4 lymphocyte count was 0.184 × 10 9 /L (range, 0.060-0.610 × 10 9 /L); 35 patients (76%) had CD4 lymphocyte counts lower than 0.200 × 10 9 /L, and only 1 patient (2%) had a CD4 cell count higher than 0.500 × 10 9 /L. Table 3 compares characteristics of pneumococcal bacteremia over time. The proportion of women who were infected increased from 37% in the first half of the study period to 52% in the second half (P=.003), whereas the case-fatality rate decreased 1.9-fold (P<.001) during the same period. During the second half of the study period, the incidence of coronary artery disease (P=.009) and valvular heart disease (P=.01) were significantly lower than in the first half, whereas the incidence of other risk factors did not change significantly. However, when the characteristics of pneumococcal bacteremia were considered separately for men and women (not shown in Table 3 ), the incidence of most risk factors significantly increased in women in the second half of the study, namely, cigarette smoking (P=.003), chronic lung disease (P=.03), malignancy (P=.04), alcoholism (P=.03), HIV infection (P<.001), and injection drug use (P=.005).
Evolution of Characteristics of Pneumococcal Bacteremia
DISCUSSION
A longitudinal study conducted in a defined community over years can provide insights into the evolution of a disease. Our surveillance is one of the largest hospitalbased analyses of pneumococcal bacteremia. In contrast to most longitudinal studies of this disease, in which the annual incidence increased over time, 3, [6] [7] [8] [9] 23, 24 we observed a stable annual incidence. In agreement with other investigators, 7,25-27 we found a clear seasonal pattern of pneumococcal bacteremia. The overall case-fatality rate in our study was 25% and emphasizes the substantial health threat of pneumococcal bacteremia. This finding was consistent with case-fatality rates of invasive pneumococcal diseases ranging between 6% and 36% that have been described by other investigators during the past 5 decades. 2, 4, [6] [7] [8] [9] [10] 15, 24, [28] [29] [30] [31] [32] [33] The multivariate analysis revealed 3 independent risk factors that adversely affected survival, namely, coronary artery disease, neutropenia, and age 65 years or older. An important finding in our study was a significant reduction in the case-fatality rate, from 33% during the first half of the study period to 17% during the second half. The decline in case-fatality rate was observed despite the similar mean age and the increased prevalence of nonsusceptible pneumococcal isolates. However, antimicrobial resistance in pneumococci found in this study population was lower than that found in most other countries. Therefore, this observation needs to be confirmed in communities with a higher prevalence of resistant strains. Three factors could have favorably affected the outcome during the second half of the study. First, an Infectious Diseases Service was implemented at our institution in 1991 and has been used hospitalwide since 1994; this service advises physicians in charge about diagnostic work-up and optimal antimicrobial treatment in patients with suspected infection. The improved outcome correlated with the broad availability of the Infectious Diseases Service. It has been reported previously that infectious diseases specialists effectively increase the appropriateness of antimicrobial treatment. 34 Our Infectious Diseases Service has improved the appropriateness of antimicrobial treatment of patients with bloodstream infections. 35 Thus, the lower case-fatality rate after July 1993 may be explained by earlier appropriate management. Unfortunately, the design of the present study does not allow us to prove this hypothesis. In our study, all patients who were not treated with an antimicrobial agent died within 48 hours of admission, underscoring the need for rapid adequate therapy as reported by other authors. 2, 7, 36 Second, factors related to pneumococcal virulence may be responsible for the lower case-fatality rate seen in the second half of the study period. Resistant bacterial strains may be less virulent. The metabolic cost of maintaining resistance to antibiotics may actually reduce virulence, which can be mutually exclusive rather than synergistic to nonsusceptibility. 17, 29 This hypothesis is supported by a case-control study by Friedland and McCracken. 37 In our study, the prevalence of penicillin-nonsusceptible pneumococci steadily increased since 1996 and reached a peak of 17% in 1999.
Third, the reduction in the prevalence of injection drug use and of underlying diseases other than HIV infection may be responsible for the decline in the case-fatality rate over time. Specifically, the decreasing incidence of coronary artery disease and valvular heart disease in the second half of the study may explain the lower case-fatality rate, but this requires confirmation from larger population-based studies. The reduction in male predominance in the second half vs the first half of the study period is likely to be the consequence of the marked increase of predisposing factors in women, which include cigarette smoking, chronic lung disease, malignancy, alcoholism, HIV infection, and injection drug use and may illustrate modification of female risk behavior observed during the past decade in Switzerland.
In Switzerland, about 0.3% of the population is HIV infected. Therefore, with 11% of our study population infected with HIV, HIV-infected individuals were markedly overrepresented. Interestingly, HIV-infected patients had a better survival rate, which was probably related to younger age and absence of coexisting comorbidity. The HIV infection was a predisposing factor for pneumococcal bacteremia but was not a risk factor for fatal outcome. Lower case-fatality rates due to pneumococcal disease in HIV-infected patients have been described, 33, [38] [39] [40] although some researchers described a higher case-fatality rate. 41, 42 In fact, most investigators noted similar mortality in HIVinfected patients and in patients not infected with HIV. 8, 10, 15 Recurrence of pneumococcal bacteremia was detected in 10 patients (3%), all of whom had an underlying medical condition. The mean interval between the first and second episode was almost 1 year (340 days), with the earliest recurrence after 72 days, suggesting a minimal risk of recurrence shortly after an episode of pneumococcal bacteremia. These findings are in accordance with other studies. [43] [44] [45] However, in contrast to high case-fatality rates in recurrent episodes in these studies (>40%), in our study, no recurrent episode was fatal. Although most patients were at risk for invasive pneumococcal infection, we were able to document pneumococcal vaccination in only 6 patients. Undervaccination of the at-risk population is a clearly missed intervention in preventing invasive pneumococcal disease. However, immunization against pneumococci may not have been recorded reliably in patients' medical records.
CONCLUSIONS
During the 15-year study period, the case-fatality rate of patients with pneumococcal bacteremia decreased significantly, despite the increased prevalence of penicillinnonsusceptible isolates. Independent risk factors for fatal outcome were coronary artery disease, neutropenia, and age 65 years or older, whereas prior respiratory tract infection and the occurrence of pneumococcal bacteremia in the second half of the study period were independent predictors of survival. HIV infection was a predisposing factor for pneumococcal bacteremia but was not a risk factor for fatal outcome.
